Xenetic Biosciences, Inc.
NCM: XBIOLive Quote
About Xenetic Biosciences, Inc.
Healthcare
Biotechnology
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
📊 Fundamental Analysis
Xenetic Biosciences, Inc. demonstrates a profit margin of -90.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 18.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -40.0%, which indicates that capital utilization is currently under pressure.
At a current price of $3.06, XBIO currently trades near the bottom of its 52-week range (10%), indicating potential value or weakness (Range: $1.90 - $13.93).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$7.22M
Trailing P/E
--
Forward P/E
-4.64
Beta (5Y)
2.21
52W High
$13.93
52W Low
$1.90
Avg Volume
25K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App